Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X) ((MARAND-X))
MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity
Sponsor: Giovanni Di Perri
Terminated
Sloww accrual and COVID-19 related problems (impossible to perform LPs)
Other terminated trials from Giovanni Di Perri
More terminations from Giovanni Di Perri
Listed as NCT03163277, this PHASE4 trial focuses on Hiv and Neurocognitive Dysfunction and remains terminated or withdrawn. Sponsored by Giovanni Di Perri, it has been updated 7 times since 2017, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2020 — Jan 2021 [monthly]
Terminated PHASE4
Status: Recruiting → Terminated
-
May 2019 — Dec 2020 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE4
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Giovanni Di Perri
For direct contact, visit the study record on ClinicalTrials.gov .